Nur77 activation has been proposed as potential in treating PD (Liu L. et al., 2021) and Nurr1 agonists can improve the behavioral symptoms and histological abnormalities in PD models (Kim et al., 2015). Here, NR4A2 is linked to Parkinson disease.